Impact of bifidobacterium-dominant gut on vaccine immunogenicity in infants: a systematic review
Intisari Sains Medis · 20.03.2026 · 17 (1) · 171-179
DOI: 10.15562/ism.v17i1.2653 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Intisari Sains Medis, online erschienen am 20.03.2026. Verfasst von Dita Martina Mahardhika und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Vaccine responses in infancy vary considerably between populations and individuals. Besides genetic and nutritional factors, the gut microbiota, particularly Bifidobacterium species, plays a crucial role in shaping immune maturation. A Bifidobacterium-dominant microbiota has been hypothesized to enhance vaccine immunogenicity, but findings across studies remain inconsistent.
Methods
This systematic review followed the PRISMA 2020 guidelines. Searches were conducted in PubMed, ScienceDirect, SpringerNature, and Cochrane databases for studies published between 2020 and 2025. Eligible articles included randomized controlled trials and observational studies assessing the relationship between Bifidobacterium abundance in infants (≤24 months) and vaccine-induced immune outcomes. Data was extracted manually and synthesized qualitatively.
Results
Eight studies (one RCT and seven observational cohorts) involving more than 2,500 infants were included. Five studies reported positive associations between Bifidobacterium dominance, particularly B. longum subsp. infantis and improved mucosal IgA or systemic IgG responses to oral (rotavirus, polio) and parenteral vaccines (pneumococcal, tetanus). However, heterogeneity was substantial, especially between high-income countries (HICs), where associations were more consistent, and low- and middle-income countries (LMICs), where null or inverse findings were more frequent.
Conclusion
Bifidobacterium dominance in early life is associated with enhanced vaccine immunogenicity, particularly for oral vaccines. Nevertheless, causality cannot be inferred because most evidence remains observational. Standardized longitudinal and interventional trials are required to confirm clinical utility and global applicability.
Zitieren
APA
Mahardhika, D. M., Ningsih, N. M. T., & Duarsa, F. A. P. (2026). Impact of bifidobacterium-dominant gut on vaccine immunogenicity in infants: a systematic review. Intisari Sains Medis, 17(1), 171-179. https://doi.org/10.15562/ism.v17i1.2653
Vancouver
Mahardhika DM, Ningsih NMT, Duarsa FAP. Impact of bifidobacterium-dominant gut on vaccine immunogenicity in infants: a systematic review. Intisari Sains Medis. 2026;17(1):171-179. doi:10.15562/ism.v17i1.2653
BibTeX
@article{Mahardhika2026,
author = {Mahardhika, Dita Martina and Ningsih, Ni Made Tirta and Duarsa, Febriyanti Angghita Putri},
title = {Impact of bifidobacterium-dominant gut on vaccine immunogenicity in infants: a systematic review},
journal = {Intisari Sains Medis},
year = {2026},
volume = {17},
number = {1},
pages = {171--179},
doi = {10.15562/ism.v17i1.2653}
}
EUVIMED